Lenalidomide After Allo Transplant

Stopped early · Phase 1

Conditions studied: Multiple Myeloma, Lymphoma

In brief

This research is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved lenalidomide for your type of cancer. Lenalidomide is a drug that alters the immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, this study will determine the effect of lenalidomide on the growth of cancer cells. Lenalidomide is approved by the FDA for the treatment of specific types of myelodysplastic syndrome (MDS) and in combination with dexamethasone for patients with multiple myeloma (MM) who have received at least 1 prior therapy. MDS and MM are cancers of the blood. It is currently being tested in a variety of cancer conditions. In this case it is considered experimental. There are some participants with multiple myeloma or lymphoma who have had very long remissions after a bone marrow/stem cell transplantation from another person. This is believed to be the effect of the donor's immune system reaction against the recipient's multiple myeloma cells. It is hoped that due to lenalidomide altering the immune system, it might be able to potentiate that reaction. This study is being done to determine if the use of lenalidomide is safe in transplant participants and if it can facilitate an immune reaction resulting in regression of the myeloma or lymphoma. During this study you will be evaluated for side effects from the treatment with lenalidomide (including graft versus host disease) and for response of the myeloma to the treatment. There will be two groups of participants in the study. The first group will be treated at a relatively low dose of lenalidomide. If this is found to be safe then the second group will be treated at a higher dose

Key facts

Study ID: NCT01750762
Run by: Beth Israel Deaconess Medical Center
People needed: 1
Starts: 2012-12-01
Expected to finish: 2014-03-01
Last updated by the study team: 2017-04-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Histologically confirmed multiple myeloma or lymphoma and evidence of disease at least 100 days after an allogeneic stem cell or bone marrow transplantation
Lymphoma patients must have measurable disease
No previous cancer therapy within 4 weeks
Life expectancy of at least 3 months
Free of prior malignancies for at least 5 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast
Must be registered into RevAssist program and willing and able to comply with RevAssist requirements
Willing to commit to abstinence or use one highly effective method of birth control and another effective method of birth control at the same time

You may not qualify if…

Pregnant or breastfeeding
Any other serious medical condition
Any condition that places the subject at unacceptable risk if he/she were to participate in the study
Use of experimental drug or therapy within 28 days of baseline
Known significant hypersensitivity to thalidomide or lenalidomide
Development of erythema nodosum if characterized by desquamating rash while taking thalidomide or similar drugs
Chemotherapy or radiotherapy within 4 weeks
Known seropositive for acute HIV, hepatitis B or C
Significant concurrent infections
Non-hematological acute GvHD and/or hematological toxicity of Grade 3 or higher
Moderate or severe chronic GVHD

Where it is running

Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.